proenzyme

(redirected from proenzymes)
Also found in: Thesaurus, Medical, Encyclopedia.
Related to proenzymes: Enzyme precursors

pro·en·zyme

 (prō-ĕn′zīm′)
n.
The inactive or nearly inactive precursor of an enzyme, converted into an active enzyme by proteolysis. Also called zymogen.
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.

proenzyme

(prəʊˈɛnzaɪm)
n
(Biochemistry) the inactive form of an enzyme; zymogen
Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014

zy•mo•gen

(ˈzaɪ mə dʒən, -ˌdʒɛn)

n.
any of various enzyme precursor molecules that may change into an enzyme as a result of catalytic change. Also called proenzyme.
[< German (1875); see zymo-, -gen]
Random House Kernerman Webster's College Dictionary, © 2010 K Dictionaries Ltd. Copyright 2005, 1997, 1991 by Random House, Inc. All rights reserved.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.proenzyme - any of a group of compounds that are inactive precursors of enzymes and require some change (such as the hydrolysis of a fragment that masks an active enzyme) to become active
organic compound - any compound of carbon and another element or a radical
Based on WordNet 3.0, Farlex clipart collection. © 2003-2012 Princeton University, Farlex Inc.
References in periodicals archive ?
The additional composition claims are a continuation from the original foundation patent in the U.S., and as a result, both method of treatment and composition claims now protects the Company's lead product candidate, PRP, a pharmaceutical composition consisting of two proenzymes, trypinsogen and chymotrypsinogen, for treating cancer.
(the 'Company') is developing a novel approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells in patients suffering from pancreatic, ovarian and colorectal cancers.
M2 PHARMA-August 13, 2019-Propanc Biopharma Publishes Key Data in Peer Reviewed Journal Confirming Anti-Cancer Stem Cell Effects of Proenzymes
PRP is the mixture of two proenzymes (trypsinogen and chymotrypsinogen) from bovine pancreas.
(4) Over 90% of the protein secretion consists of proenzymes or enzymes that pass almost entirely into the duodenum; only a small fraction of these enzymes reaches the blood.
MMPs are secreted as inactive proenzymes or zymogens, which are activated by the cleavage of the prodomain [18].
A study indicated that improved proenzymes were released from the injured pancreas in response to [AFB.sub.1] (200 [micro]g/kg) in Cherry Valley ducks [8].
They are synthesised and secreted in the form of inactive zymogens (proenzymes) by most of cells in the human body [1].
Considering that MMPs are synthesized and secreted as inactive proenzymes (zymogens), a metalloproteinase-specific activation test was applied to differentiate active forms of MMPs and MMP precursors in OF.
MMPs are a large family of calcium-dependent zinc-containing endopeptidases, which are typically composed of Ave structural zones: 1) pro-peptide, which maintains the latency of the proenzymes; 2) catalytic domain, including zinc-ion binding site; 3) hydrophobic signal peptide; 4) hemopexin-like C-terminal domain, which is associated with the substrate specificity; 5) hinge region, containing prolines.
Most ADAMs are synthesized as proenzymes, in which the N-terminal and inhibiting prodomain is released by furin-mediated cleavage during the maturation process.
These MMPs are released as inactive proenzymes (pro-MMPs) and on activation (by proteolytic cleavage of a small peptide) are capable of digesting all components of an ECM [8-11].